Icagen (ICGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Icagen (ICGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	1/10/2007 9:39:52 PM
	of 11

Icagen Up on Pain Research Update Keeping the world from forgetting the company? Jason Jan. 10, 2007, 9:33AM © 2007 The Associated Press RESEARCH TRIANGLE PARK, N.C. — Biotech drug developer Icagen Inc. said Wednesday it identified compounds that were effective in animal tests to treat chronic pain. The company said it found certain compounds in its research program into sodium channel targets that were effective in relieving neuropathic and inflammatory pain in animals. Sodium channels are proteins that regulate sodium ions through the walls of cells such as nerve cells. Icagen holds an exclusive license on a patents concerning the sodium channel target SCN9A, which research suggests is connected to the ability to feel pain. Icagen licenses the patents from Allelix Neuroscience. Shares of Icagen rose 5 cents, or 3.5 percent, to $1.50 in morning trading on the Nasdaq. Shares have traded between 66 cents and $9.25 over the past year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next